Cullinan Therapeutics (CGEM) News Today $12.58 -0.52 (-3.97%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period What is Leerink Partnrs' Forecast for CGEM FY2025 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2025 earnings estimates for Cullinan Therapeutics in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst A. Berens now expects that the company will pNovember 20 at 6:58 AM | marketbeat.comCullinan Therapeutics: Promising Developments and Strategic Growth in Autoimmune TherapiesNovember 20 at 12:40 AM | markets.businessinsider.comCullinan Management (CGEM) Has a New Rating from WedbushNovember 20 at 12:40 AM | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical AnalysisNovember 19 at 3:59 AM | americanbankingnews.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 6.3% - Time to Sell?Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 6.3% - Here's What HappenedNovember 15, 2024 | marketbeat.comCullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024November 14, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)November 11, 2024 | markets.businessinsider.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 8,000 Shares of StockNovember 8, 2024 | insidertrades.comCullinan Therapeutics sees cash runway into 2028November 7, 2024 | markets.businessinsider.comCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comCullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNovember 5, 2024 | globenewswire.comCullinan Therapeutics to present preclinical data for CLN-978November 4, 2024 | markets.businessinsider.comCullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024November 4, 2024 | globenewswire.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by BrokeragesShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have been given a consensus rating of "Buy" by the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month targNovember 3, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock, Option ChainNovember 1, 2024 | benzinga.comCullinan Therapeutics (NASDAQ:CGEM) Stock Quotes, Forecast and News SummaryNovember 1, 2024 | benzinga.comWhat is Leerink Partnrs' Estimate for CGEM FY2027 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at Leerink Partnrs issued their FY2027 EPS estimates for shares of Cullinan Therapeutics in a report released on Monday, October 28th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of $0.54 per sharOctober 30, 2024 | marketbeat.comUBS Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy RecommendationOctober 25, 2024 | msn.comCullinan Therapeutics initiated with a Buy at UBSOctober 24, 2024 | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) Receives New Coverage from Analysts at UBS GroupUBS Group assumed coverage on shares of Cullinan Therapeutics in a research report on Thursday. They issued a "buy" rating and a $30.00 price objective for the company.October 24, 2024 | marketbeat.comSG Americas Securities LLC Sells 70,115 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)SG Americas Securities LLC reduced its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 82.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,057 shares of the cOctober 22, 2024 | marketbeat.comCGEM Cullinan Therapeutics, Inc.October 19, 2024 | seekingalpha.comCullinan Therapeutics (NASDAQ:CGEM) Trading Down 3.2% - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 3.2% - Here's What HappenedOctober 18, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest UpdateCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 9,210,000 shares, an increase of 9.4% from the September 15th total of 8,420,000 shares. Based on an average daily volume of 650,600 shares, the short-interest ratio is presently 14.2 days. Currently, 23.6% of the shares of the company are sold short.October 17, 2024 | marketbeat.comCullinan Therapeutics Gets FDA Approval for Lupus Treatment StudyOctober 17, 2024 | marketwatch.comCullinan Therapeutics (NASDAQ:CGEM) Trading Up 7% - Time to Buy?Cullinan Therapeutics (NASDAQ:CGEM) Trading 7% Higher - Here's WhyOctober 16, 2024 | marketbeat.comCullinan Therapeutics' (CGEM) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $28.00 target price on shares of Cullinan Therapeutics in a report on Wednesday.October 16, 2024 | marketbeat.comCullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusOctober 16, 2024 | globenewswire.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by AnalystsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been assigned an average recommendation of "Buy" from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12-month price oOctober 9, 2024 | marketbeat.comAlgert Global LLC Has $696,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Algert Global LLC trimmed its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 49.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,884 sharesOctober 6, 2024 | marketbeat.comPerceptive Advisors LLC Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Perceptive Advisors LLC purchased a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 749,916 shares of the company's stock, valued at approximatelySeptember 30, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP trimmed its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 29.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,049,172 shares of the company's stSeptember 28, 2024 | marketbeat.comLynx1 Capital Management LP Buys Shares of 377,323 Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Lynx1 Capital Management LP purchased a new position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 377,323 shares of the company's stock, valued at approxiSeptember 27, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Has $57.21 Million Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Deerfield Management Company L.P. Series C grew its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 188.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,280,237 shares of the company's stock after buyiSeptember 26, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.2% Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.2%September 23, 2024 | marketbeat.comAustralian HREC grants clearance for Cullinan Therapeutics’ SLE treatment trialSeptember 19, 2024 | msn.comCullinan Management (CGEM) Gets a Buy from WedbushSeptember 19, 2024 | markets.businessinsider.comE Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)E Fund Management Co. Ltd. purchased a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 74,827 shares of the company's stock, valueSeptember 18, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.5%Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.5% HigherSeptember 17, 2024 | marketbeat.comCullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusSeptember 17, 2024 | globenewswire.comBank of New York Mellon Corp Buys 43,757 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Bank of New York Mellon Corp raised its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 46.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 137,997 shares of the coSeptember 17, 2024 | marketbeat.comTD Cowen Keeps Their Buy Rating on Cullinan Management (CGEM)September 16, 2024 | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $17.95Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up to $17.95September 16, 2024 | marketbeat.comCullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024September 14, 2024 | globenewswire.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 8,000 SharesSeptember 10, 2024 | insidertrades.comCullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune DiseaseAugust 30, 2024 | seekingalpha.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesAugust 28, 2024 | globenewswire.comWe Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business GrowthAugust 24, 2024 | finance.yahoo.comAssenagon Asset Management S.A. Invests $1.99 Million in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Assenagon Asset Management S.A. acquired a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 114,195 shares ofAugust 22, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Up 3.6%Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 3.6%August 21, 2024 | marketbeat.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.480.45▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼83▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MGNX News BDTX News IPHA News HCM News VERA News MOR News SWTX News KYMR News VCEL News GMTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
